IMNN Stock — Imunon Inc

Imunon Inc (IMNN)

Updated October 16, 2026.

IMNN is a Stock. Its deepest 1-year drawdown was 80.0%.

Imunon is a clinical-stage biotechnology company developing immunotherapies and vaccines, with its lead program being IMNN-001, a DNA-based immunotherapy in Phase 3 trials for advanced ovarian cancer and earlier-stage development for colorectal, pancreatic, and brain cancers, alongside a COVID-19 booster vaccine candidate and proprietary non-viral DNA technology platforms. The company does not currently distribute income to shareholders. This security appeals primarily to investors seeking exposure to early-stage biotech development rather than those focused on dividend income.

IMNN performance

Returns are updating. IMNN's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 80.0%.

IMNN key facts

Asset type

Stock

Asset class

Equity

Inception date

07/24/1995

Distribution frequency

None

Last close

$1.02 (as of 2026-10-16)

Market cap

$5,723,631

Average volume

55510.0

Beta

2.005

Payout ratio

0.0%

Forward P/E

16.7785

EPS

$-3.84

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

IMNN risks and drawbacks

The deepest 1-year drawdown on record here is 80.0%.

Who may consider IMNN — and who may not

It is a weaker fit for investors who need monthly cash flow (IMNN does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on IMNN

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions